Lanean...
Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations
PURPOSE: Although EGFR-mutated patients generally do not benefit from checkpoint inhibitors (ICIs), some patients in the KEYNOTE-001 study consistently benefited from this treatment. This study investigated immune microenvironment characteristics to identify the subgroup of patients that may benefit...
Gorde:
| Argitaratua izan da: | Lung Cancer (Auckl) |
|---|---|
| Egile Nagusiak: | , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Dove
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7490071/ https://ncbi.nlm.nih.gov/pubmed/32982525 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/LCTT.S262822 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|